Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 3 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences is active in the Biotechnology & Pharmaceuticals technology area with 2 pending office actions. These 2 pending office actions are distributed across 2 distinct art units, which suggests that the current patent applications involve different technical sub-specialties. Practitioners must be prepared to navigate the different examination cultures and procedural requirements of the 2 distinct art units. The success of the 2 pending office actions depends on addressing the specific technical standards and precedents prevalent in each of these units.
The prosecution effort involves 2 distinct examiners, meaning that each pending matter is reviewed by a different official. JADHAO, SAMADHAN JAISING is the busiest examiner for the portfolio and is responsible for 1 pending office action. With 2 distinct examiners managing the 2 pending office actions, there is no centralization of the examination process at the individual level. This fragmentation requires practitioners to tailor their advocacy to the specific preferences of JADHAO, SAMADHAN JAISING and the other assigned examiner. Effectively managing the 2 pending office actions requires a high degree of coordination across the 2 distinct art units to resolve the 1 pending office action assigned to the busiest examiner.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARRERA, IMMACULADA | 1 | 30.0% | +80.8% |
| JADHAO, SAMADHAN JAISING | 1 | 46.2% | +47.0% |
| JONES, DAMERON LEVEST | 1 | 67.8% | +31.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 56d overdue |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 33d |
| 18260309 | HUMAN PAPILLOMAVIRUS TYPE 31 CHIMERIC PROTEIN AND USE THEREOF | BARRERA, IMMACULADA | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 56d overdue |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 33d |
| 18260309 | HUMAN PAPILLOMAVIRUS TYPE 31 CHIMERIC PROTEIN AND USE THEREOF | BARRERA, IMMACULADA | — |
| Art Unit | Apps |
|---|---|
| 1671 | 1 |
| 1672 | 1 |
| 1618 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260309 | HUMAN PAPILLOMAVIRUS TYPE 31 CHIMERIC PROTEIN AND USE THEREOF | BARRERA, IMMACULADA | 1671 | §103§112 | Final Rejection | — | Pending | Jul 03, 2023 |
| 18254576 | MODIFIED HUMAN PAPILLOMAVIRUS TYPE 52 L1 PROTEIN AND USE THEREOF | JADHAO, SAMADHAN JAISING | 1672 | §102§103 | Final Rejection | 33d | Pending | May 25, 2023 |
| 17627805 | ANTI-INFECTION EFFECTS OF HNRNPA2B1 AND USE THEREOF | JONES, DAMERON LEVEST | 1618 | §102§112 | Final Rejection | 56d overdue | Pending | Jan 17, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialInstitute Of Basic Medical Sciences Chinese Academy Of Medical Sciences has 3 pending office actions as of October 2026, spread across 3 art units and 3 examiners.
Immaculada Barrera has the most, with 1 of Institute Of Basic Medical Sciences Chinese Academy Of Medical Sciences's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
